MRTX News and Press, Mirati Therapeutics Inc. From 06/05/20

SAN DIEGO , June 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the upcoming 41 st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020 . Charles M. Baum , M.D., Ph.D.,...

SAN DIEGO , May 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that Joseph Leveque , M.D. has been named Chief Medical Officer effective May 18, 2020 . Isan Chen , M.D., will step down as Chief Medical...

SAN DIEGO , May 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the Company's pipeline of novel therapeutics in three presentations at the American Association for Cance...

Mirati Therapeutics (NASDAQ: MRTX ): Q1 GAAP EPS of -$2.02 misses by $0.34 . More news on: Mirati Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN DIEGO , May 7, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the first quarter ended March 31, 2020 . "Despite the challenges many are facing related to the COVI...

Axcella Health (NASDAQ: AXLA ) initiated with Buy rating and $10 (115% upside) price target at BTIG Research. More news on: Axcella Health Inc., Viking Therapeutics, Inc., Y-mAbs Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Shares of Verastem Oncology (NASDAQ: VSTM) , a biotechnology company developing novel cancer therapies, are sliding after a highly anticipated data drop failed to impress investors. Shares of the biotech stock were down 42.9% as of 12:12 p.m. EDT on Monday. This year, the American Associatio...

We are short shares of Mirati Therapeutics, a $4.6bn clinical-stage biopharmaceutical company whose lead drug candidate, MRTX-849, is a small-molecule KRAS inhibitor (KRASi). The KRAS protein plays a critical role in cell proliferation and differentiation, and mutations of the gene that encode...

Kerrisdale Capital reports that it is short Mirati Therapeutics ( MRTX -5.9% ) based on, what it considers, dim prospects for lead drug MRTX-849, citing early-stage data showing a low response rate and "incredibly short-lived" duration of response in lung cancer (NSCLC) patients. Ke...

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Buy rating and $60 (33% upside) price target at Jefferies. More news on: ACADIA Pharmaceuticals Inc., eHealth, Inc., Lumos Pharma, Inc., Healthcare stocks news, Stocks on the move, , Read more ...